Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study

European Neuropsychopharmacology

Volumn 24, Issue 7, 2014, Pages 1078-1085

  Fervaha, Gagan ^a,b   Agid, Ofer ^a,b,c   Takeuchi, Hiroyoshi ^a,c   Foussias, George ^a,b,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic treatment; Life satisfaction; Outcome; Quality of life; Schizophrenia; Well being

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POSITIVE SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; DOUBLE BLIND PROCEDURE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PROSPECTIVE STUDY; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PERSONAL SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES;

EID: 84902319814     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.03.001     Document Type: Article

References (50)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. Alonso J., Croudace T., Brown J., Gasquet I., Knapp M.R., Suarez D., Novick D. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009, 12:536-543.
3. Appelbaum P.S., Grisso T. MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) 2001, Professional Resource Press, Sarasota, FL.
4. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Adademic Press, New York. 2nd ed.
7. Cramer J.A., Rosenheck R., Xu W., Thomas J., Henderson W., Charney D.S. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr. Bull. 2000, 26:659-666.
8. Diener E. Subjective well-being. Psychol. Bull. 1984, 95:542-575.
9. Diener E., Emmons R.A., Larsen R.J., Griffin S. The Satisfaction With Life Scale. J. Pers. Assess. 1985, 49:71-75.
10. Eack S.M., Newhill C.E. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33:1225-1237.
11. Fervaha G., Agid O., Takeuchi H., Foussias G., Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophr. Res. 2013, 151:203-208.
12. First M.B. User[U+05F3]s Guide for the Structured Clinical Interview for DSM-IV axis I Disorders SCID-I: Clinician Version 1997, Amer Psychiatric Pub Inc., Washington, DC.
13. Gill T.M., Feinstein A.R. A critical appraisal of the quality of quality-of-life measurements. J. Am. Med. Assoc. 1994, 272:619-626.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised 1976, National Institute of Health, Department of Health, Education, and Welfare, Rockville, MD.
15. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
16. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983, 13:177-183.
17. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
18. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
20. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
21. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., Adler L.W., Manschreck T.C., Swartz M., Rosenheck R., Perkins D.O., Walker T.M., Stroup T.S., McEvoy J.P., Lieberman J.A. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31:2033-2046.
22. Keefe R.S., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., Gold J.M., Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. Bull. 2003, 29:45-55.
23. Lehman A.F. The well-being of chronic mental patients. Arch. Gen. Psychiatry 1983, 40:369-373.
24. Lehman A.F. A quality of life interview for the chronically mentally ill. Eval. Program Plan. 1988, 11:51-62.
25. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161:1-56.
26. Lehman A.F., Postrado L.T., Rachuba L.T. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual. Life Res. 1993, 2:327-333.
27. Leifker F.R., Patterson T.L., Heaton R.K., Harvey P.D. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 2011, 37:334-343.
28. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
29. Leucht S., Engel R.R. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology 2006, 31:406-412.
30. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
31. McEvoy J.P., Apperson L.J., Appelbaum P.S., Ortlip P., Brecosky J., Hammill K., Geller J.L., Roth L. Insight in schizophrenia. Its relationship to acute psychopathology. J. Nerv. Ment. Dis. 1989, 177:43-47.
32. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
33. Melle I., Rossberg J.I., Joa I., Friis S., Haahr U., Johannessen J.O., Larsen T.K., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P., McGlashan T. The development of subjective quality of life over the first 2 years in first-episode psychosis. J. Nerv. Ment. Dis. 2010, 198:864-869.
34. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
35. Myers D.G., Diener E. The pursuit of happiness. Sci. Am. 1996, 274:70-72.
36. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol 1995, 10(Suppl. 3):S133-S138.
37. Narvaez J.M., Twamley E.W., McKibbin C.L., Heaton R.K., Patterson T.L. Subjective and objective quality of life in schizophrenia. Schizophr. Res. 2008, 98:201-208.
38. Rapaport M.H., Clary C., Fayyad R., Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am. J. Psychiatry 2005, 162:1171-1178.
39. Reine G., Lancon C., Di Tucci S., Sapin C., Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr. Scand. 2003, 108:297-303.
40. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
41. Ritsner M., Gibel A., Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Qual. Life Res. 2006, 15:515-526.
42. Rosenheck R.A., Davis S., Covell N., Essock S., Swartz M., Stroup S., McEvoy J., Lieberman J. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr. Res. 2009, 107:22-29.
43. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970, 212:11-19.
44. Sprangers M.A., Schwartz C.E. Integrating response shift into health-related quality of life research: a theoretical model. Soc. Sci. Med. 1999, 48:1507-1515.
45. Stroup T.S., Lieberman J.A., McEvoy J.P., Davis S.M., Swartz M.S., Keefe R.S., Miller A.L., Rosenheck R.A., Hsiao J.K. Results of phase 3 of the CATIE schizophrenia trial. Schizophr. Res. 2009, 107:1-12.
46. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Capuano G.A., Rosenheck R.A., Keefe R.S., Miller A.L., Belz I., Hsiao J.K. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am. J. Psychiatry 2007, 164:415-427.
47. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 2006, 163:611-622.
48. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29:15-31.
49. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436.
50. Voruganti L., Heslegrave R., Awad A.G., Seeman M.V. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 1998, 28:165-172.